Wheeler's biomanufacturing programs will initially focus on antibody therapeutics. The company's discovery-to-investigational new drug (IND) programs are designed to provide emerging biopharma companies a faster and more predictable path to the clinic.

Wheeler is located in Oklahoma City with pilot labs located inside Alloy's Boston facility. The company will open a 35,000-sq-ft cGMP facility in Oklahoma City late next year and will have preferred access to expand its biomanufacturing offering to commercial scale production in the recently announced 400,000-sq-ft manufacturing complex in the city's Innovation District.

Founded in 2017 and privately funded, Alloy facilitates access to the entire drug discovery community from academic scientists and small and medium biotechs to the largest biopharmas, the company said. Alloy's lead offering is the ATX-Gx platform, a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains.